European Union - English - EMA (European Medicines Agency)

bavarian nordic a/s - modified vaccinia ankara - bavarian nordic (mva-bn) virus - smallpox vaccine; monkeypox virus - other viral vaccines, - active immunisation against smallpox, monkeypox and disease caused by vaccinia virus in adults (see sections 4.4 and 5.1).the use of this vaccine should be in accordance with official recommendations.

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - cyd dengue virus serotype 1; cyd dengue virus serotype 2; cyd dengue virus serotype 3; cyd dengue virus serotype 4 - injection, powder, for suspension - cyd dengue virus serotype 1 4.5 - 6.0 log10 ccid50/dose; cyd dengue virus serotype 2 4.5 - 6.0 log10 ccid50/dose; cyd dengue virus serotype 3 4.5 - 6.0 log10 ccid50/dose; cyd dengue virus serotype 4 4.5 - 6.0 log10 ccid50/dose

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - cyd dengue virus serotype 1; cyd dengue virus serotype 2; cyd dengue virus serotype 3; cyd dengue virus serotype 4 - injection, powder, for suspension - cyd dengue virus serotype 1 4.5 - 6.0 log10 ccid50/dose; cyd dengue virus serotype 2 4.5 - 6.0 log10 ccid50/dose; cyd dengue virus serotype 3 4.5 - 6.0 log10 ccid50/dose; cyd dengue virus serotype 4 4.5 - 6.0 log10 ccid50/dose

Canada - English - Health Canada

sanofi pasteur limited - smallpox vaccine dried - powder for solution - 100m - smallpox vaccine dried 100m - vaccines

Canada - English - Health Canada

bavarian nordic as - modified vaccinia virus (ankara-bavarian nordic) - suspension - 50000000ccid50 - modified vaccinia virus (ankara-bavarian nordic) 50000000ccid50 - vaccines

European Union - English - EMA (European Medicines Agency)

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - dengue - vaccines - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4.2, 4.4 and 4.8).the use of dengvaxia should be in accordance with official recommendations.

European Union - English - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - hemorrhagic fever, ebola - vaccines - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.,

European Union - English - EMA (European Medicines Agency)

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vaccines - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age. the use of this vaccine should be in accordance with official recommendations.

Canada - English - Health Canada

merck canada inc - ebola zaÏre vaccine (rvsv [delta] g-zebov-gp, live) - solution - 72000000pfu - ebola zaÏre vaccine (rvsv [delta] g-zebov-gp, live) 72000000pfu

European Union - English - EMA (European Medicines Agency)

takeda gmbh - dengue virus, serotype 2, expressing dengue virus, serotype 1, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 3, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 4, surface proteins, live, attenuated, dengue virus, serotype 2, live, attenuated - dengue - vaccines - qdenga is indicated for the prevention of dengue disease in individuals from 4 years of age.the use of qdenga should be in accordance with official recommendations.